ABSTRACT
channels and receptors. We characterized the effect of Zn 2ϩ on the functional properties of the ␤ 2 -adrenergic receptor (␤ 2 AR). We found that physiological concentrations of Zn 2ϩ increased agonist affinity and enhanced cAMP accumulation stimulated by submaximal concentrations of the ␤AR agonist isoproterenol. These results provide evidence that Zn 2ϩ released at nerve terminals may modulate signals generated by the ␤ 2 AR in vivo.
Several groups have used Zn 2ϩ together with engineered metal ion binding sites as a method to study G proteincoupled receptor (GPCR) structure (Sheikh et al., 1996 (Sheikh et al., , 1999 Thirstrup et al., 1996; Elling et al., 1999) . In these studies, Zn 2ϩ is used as a ligand for a binding pocket introduced into a receptor by one or more histidine substitutions. This method has provided insight into the proximity and relative orientation of transmembrane domains (Thirstrup et al., 1996) , as well as the mechanism of receptor activation (Sheikh et al., 1996 (Sheikh et al., , 1999 Elling et al., 1999) . However, there is considerable evidence that Zn 2ϩ may be a physiological regulator of receptor function. Zn 2ϩ is an abundant ion in the central nervous system (Schetz et al., 1999) and may be present at high enough concentrations in specific synapses to have a physiological role in regulating GPCR function in vivo. The ␤ 2 -adrenergic receptor (␤ 2 AR) mediates adrenergic responses in both the central nervous system and the sympathetic nervous system. We therefore examined the effects of Zn 2ϩ on ␤ 2 AR function. At low concentrations (1-20 M), Zn 2ϩ increases agonist affinity and enhances cAMP accumulation in response to submaximal concentrations of a ␤-agonist. At high concentrations (Ͼ500 M), Zn 2ϩ alters both K D and B max values for the antagonist dihydroalprenolol (DHA). These results demonstrate that Zn 2ϩ is a positive allosteric modulator of agonist binding for the ␤ 2 AR and suggest that Zn 2ϩ may be a physiologically relevant regulator of ␤ 2 AR function in vivo.
Urea Treatment of Membranes. Membranes were extracted with 7 M urea to remove G protein subunits (Lim and Neubig, 2001 ). The urea solution was prepared by dissolution of urea crystals in a buffer containing 50 mM Tris-HCl, pH 7.4, 5 mM MgCl 2 , 1 mM EDTA with protease inhibitors (25 g/ml leupeptin and 16 g/ml benzamidine) at room temperature and then kept on ice until use. Sf9 membranes expressing the ␤ 2 AR were pelleted (40,000g for 10 min) and resuspended to ϳ1 mg/ml in freshly prepared 7 M urea solution. The membranes were homogenized 10 times and incubated for 30 min with stirring. The membranes were centrifuged at 40,000g for 30 min then washed with 75 mM Tris-HCl, pH 7.4, containing protease inhibitors. The final pellet was resuspended to a final concentration of ϳ1 mg/ml and stored in aliquots at Ϫ80°C.
Expression and Purification of ␤ 2 AR Receptor. The human ␤ 2 AR, epitope tagged at the amino terminus with the FLAG eptiope (Sigma) and tagged at the carboxy terminus with six histidines, was expressed in Sf9 cells and purified as described previously (Kobilka, 1995 Solubilized Binding Assays. Binding assays on purified, detergent-solubilized receptor were carried out in 100-l volumes in high-salt buffer (20 mM Tris-HCl, pH 7.5, 500 mM NaCl, and 0.1% n-dodecyl maltoside). The binding assays were stopped and free [ 3 H]DHA separated from bound by desalting on 2-ml Sephadex G50 column (4 ϫ 0.5 cm) by using ice-cold high-salt buffer. Nonspecific binding was determined in the presence of 10 M alprenolol.
Dissociation Rate Kinetic Assay. The effect of zinc on the rate of antagonist dissociation from ␤ 2 AR was examined by measuring the k off in the absence and presence of 1 mM Zn 2ϩ . Membranes were suspended in 75 mM Tris-HCl, pH 7. 35 S]GTP␥S by filtration through GF/C filters, followed by three washes with 3 ml of cold magnesium binding buffer. Filter-bound radioactivity was determined by liquid scintillation counting.
cAMP Accumulation. The production of cAMP was determined by adenylyl cyclase activation FlashPlate assay (PerkinElmer Life Sciences), in which 96-well plates are coated with solid scintillant to which anti-cAMP antibody has been bound. Briefly, HEK293 cells expressing human ␤ 2 AR were detached and washed four times in 1ϫ phosphate-buffered saline without Ca 2ϩ /Mg 2ϩ , and then resuspended to a density of approximately 2 ϫ 10 6 cells/ml in stimulation buffer (1ϫ phosphatebuffered saline, without calcium/magnesium, with 700 M 3-isobutyl-1-methylxanthine, 0.1% protease-free bovine serum albumin, and 0.09% chloroacetamide) from PerkinElmer Life Sciences. Ligands (25 l each) were diluted in Milli-Q water with various concentrations and dispensed to the flashplate. Resuspended whole cells (50 l) were added to the ligand-loaded plate and stimulated at 37°C for 10 min before lysing cells with 100 l of Detection Buffer (Invitrogen) containing 125 I-cAMP, permeabilizer, and 0.09% sodium azide as provided by the manufacturer. After 2 h of incubation at room temperature, radioactivity was counted. To determine the concentrations of cAMP in the sample, cAMP standards were run in the same plate and expressed as picomoles per well.
Miscellaneous. Protein was determined using the DC protein assay kit (Bio-Rad, Hercules, CA). Data were analyzed by nonlinear regression analysis with Prism program (GraphPad Software, San Diego, CA).
Results

Effect of Zn
2؉ on Antagonist Binding. To examine the effect of Zn 2ϩ on antagonist binding, we performed radioligand binding studies by using [ 3 H]DHA, a neutral antagonist. As shown in Fig. 1A , a significant effect of Zn 2ϩ on DHA binding was observed only at concentrations of Zn 2ϩ Ͼ500 M, where DHA binding was reduced by 40 Ϯ 2% (Fig. 1A) . Saturation binding studies in the presence or absence of 1 mM Zn 2ϩ caused an increase of nearly 3-fold in apparent K D value for DHA (1.4 Ϯ 0.2 nM control, 4.9 Ϯ 1.2 nM with Zn 2ϩ ) with a 40% decrease in B max (Fig.  1B) . These results suggest that Zn 2ϩ may function as a noncompetitive blocker of antagonist binding; however, we found that 1 mM Zn 2ϩ slowed the rate of DHA dissociation (Fig. 1C) . Moreover, the effect of Zn 2ϩ on antagonist binding is not fully reversible in membrane-bound ␤ 2 AR ( Fig.  2A) . Note that Zn 2ϩ also inhibits binding of antagonist to purified, detergent-solubilized ␤ 2 AR; however, this inhibition is almost completely reversible after chelation of Zn 2ϩ by EDTA (Fig. 2B ). These results suggest that some of the effects of Zn 2ϩ on antagonist binding may be caused by nonspecific effects of Zn 2ϩ on phospholipids.
2؉ on High-and Low-Affinity Agonist Binding. We examined the effect of Zn 2ϩ on agonist binding in membranes expressing the ␤ 2 AR with and without G s␣ . For these experiments, we used tetG s␣ . We have shown previously that tetG s␣ couples more efficiently to ␤ 2 AR than does wild-type G s␣ (Lee et al., 1999) . In membranes expressing the ␤ 2 AR with tetG s␣ , we observed a biphasic curve with a high-affinity, GTP␥S-sensitive component (Fig. 3) . To study the effect of Zn 2ϩ on agonist binding affinity, isoproterenol competition binding studies were done using 1 nM antagonist [ 3 H]DHA in the presence of varying concentrations of Zn 2ϩ (Fig. 4 , A-C). As shown in Fig. 4A , as little as 20 M Zn 2ϩ resulted in a change of the apparent biphasic nature of the competition curve with an increase in K H . We also observed a decrease in K L ,
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Swaminath et al. which was even greater at 100 M Zn 2ϩ ( Fig. 4B ), a concentration at which we observed no effects on antagonist binding. A smaller decrease in K L was observed at 1 mM Zn 2ϩ ( Fig. 4C ), a concentration that also reduces antagonist affinity. We observed similar effects on agonist binding affinity in membranes expressing the ␤ 2 AR without tetG s␣ , where only a small amount of high-affinity binding is detected (Fig. 5A ), as well as in membranes treated with 7 M urea to remove heterotrimeric G proteins (Fig. 5B) . Thus, at relatively low concentrations, Zn 2ϩ induces an increase in agonist affinity for the uncoupled receptor.
The receptor used in the studies described thus far contains a hexahistidine tail on the carboxyl terminus to facilitate receptor purification. However, we observed identical effects of Zn 2ϩ on antagonist binding (data not shown) and on agonist binding in membranes expressing a ␤ 2 AR without a carboxyl-terminal hexahistidine sequence (Fig. 5C) 3 H]DHA) and either 5 mM EDTA or nothing was added and incubated for 1 h at room temperature. The membranes were then harvested by rapid filtration and soluble receptor was harvested by gel filtration as described under Experimental Procedures. Data shown are the mean Ϯ S.D. of three independent experiments performed either in duplicate for purified protein or triplicate for membranes.
Allosteric Modulation of ␤ 2 AR by Zn
2؉
To confirm that the Zn 2ϩ -mediated increase in agonist affinity was caused by a direct interaction between Zn 2ϩ and the ␤ 2 AR, we examined the influence of Zn 2ϩ on purified, detergent-solubilized ␤ 2 AR. As shown in Fig. 6C (Fig. 7) . Co 2ϩ had an effect on agonist affinity similar to Zn 2ϩ , but no significant effect on antagonist affinity (Fig. 7A) . Ni 2ϩ had no significant effect on either agonist or antagonist affinity (Fig.  7B) .
Inhibition of Gs Function by Zn 2؉ . Our competition binding studies (Fig. 4) suggest that Zn 2ϩ uncouples the receptor from Gs. To further examine the effect of Zn 2ϩ on the interaction of the ␤ 2 AR and G s␣ , receptor-mediated GTP␥S binding was performed in Sf9 membranes coexpressing ␤ 2 AR and tetG s␣ . Consistent with the results of Sheikh et al. (1999) , we found that Zn 2ϩ inhibited stimulation of GTP␥S binding by the agonist isoproterenol with an IC 50 of 7.2 M (Fig. 8) . However, we also found that Zn 2ϩ inhibited basal GTP␥S binding to purified Gs ␣ (data not shown), suggesting that the uncoupling of ␤ 2 AR and Gs is caused by a direct effect of Zn 2ϩ on G s␣ , possibly by competing for the Mg 2ϩ binding site. Effect of Zn 2؉ on Isoproterenol-Stimulated cAMP Accumulation. The studies described above were done on membrane fragments or purified receptor in which Zn 2ϩ has equal access to both cytoplasmic and extracellular domains of the ␤ 2 AR. Therefore, they do not provide information about the location of the Zn 2ϩ binding site(s) responsible for the functional effects of Zn 2ϩ on agonist and antagonist binding. In vivo, Zn 2ϩ released from synaptic vesicles would have access to extracellular domains of the receptor. Diffusion or transport of Zn 2ϩ across the plasma membrane would limit access to intracellular domains. We therefore examined the effect of Zn 2ϩ on isoproterenolstimulated cAMP accumulation in intact HEK293 cells expressing the wild-type (non-histidine-tagged) ␤ 2 AR. Isoproterenol dose-response studies revealed that at Zn 2ϩ concentrations 100 M or greater the maximal cAMP accumulation was decreased (Fig. 9A ). When these data were plotted as the percentage of the maximal isoproterenolstimulated cAMP, we observed a small decrease in EC 50 in the presence of 1 M Zn 2ϩ (Fig. 9B ). To further examine the effect of Zn 2ϩ on isoproterenol-stimulated cAMP accumulation, cells were exposed to increasing concentrations of Zn 2ϩ in the presence of 0 to 1 nM isoproterenol. Maximal cAMP accumulation was observed at 1 M Zn 2ϩ in the presence of isoproterenol, but Zn 2ϩ had no effect in the absence of isoproterenol (Fig. 9C) . Moreover, Zn 2ϩ did not Fig. 3 . Effect of GTP␥S on isoproterenol competition of DHA binding to Sf9 membranes expressing ␤ 2 AR together with tetG s␣ . Isoproterenol competition in presence and absence of unlabeled GTP␥S (10 M) was performed as described under Experimental Procedures. Reaction mixtures contained 10 g of protein/tube. The membranes expressing the protein were 15.7 pmol/mg. Data shown are the mean Ϯ S.D. of three independent experiments performed in triplicate. Binding data were analyzed for best fit to two affinity states. augment cAMP accumulation stimulated by either 10 or 100 M forskolin (Fig. 9D) .
Discussion
Our results demonstrate that at micromolar concentrations, Zn 2ϩ is a positive allosteric modulator of agonist binding; at higher concentrations, Zn 2ϩ has complex effects on antagonist binding. Allosteric modulation of ligand binding has been observed for several GPCRs. These modulators include physiologically relevant ions as well as small organic molecules. A large number of compounds allosterically increase binding affinity for muscarinic receptor antagonists. Allosteric regulation can be demonstrated in all five subtypes of muscarinic receptors, but the m2 receptor seems to be the most sensitive (Tucek and Proska, 1995) . Although most allosteric modulators for the muscarinic receptors primarily affect antagonist binding, allosteric modulation of agonist binding has also been described previously (Jakubik et al., 1997) .
In addition to the muscarinic receptor, allosteric compounds have been identified for the A1 adenosine receptor. The 2-amino-3-benzoylthiophene PD 81,723 has been shown to enhance agonist binding and G protein coupling in a Mg 2ϩ -dependent manner (Bhattacharya and Linden, 1995; Musser et al., 1999) . 6 . Effect of zinc on the agonist affinity. A, effect of Zn 2ϩ on [ 3 H]DHA binding in presence and absence of 100 nM isoproterenol was determined using Sf9 membranes expressing ␤ 2 AR (7 pmol/mg). Assay mixtures contained ϳ25 g of membrane protein, 1 nM [ 3 H]DHA, and 10 M GTP␥S. Nonspecific binding was less than 10% of total binding. Data represent the mean Ϯ S.D. of three independent experiments. Each of these experiments was performed in triplicate. B, effect of Zn 2ϩ on agonist affinity in urea-treated membranes expressing ␤ 2 AR (12.6 pmol/mg). The reaction mixtures contained ϳ20 g of membrane protein and 2 nM [ 3 H]DHA. Data represent the mean Ϯ S.D. of two independent experiments. Each of these experiments was performed in triplicate. C, effect of Zn 2ϩ on agonist affinity in purified, detergent-solubilized ␤ 2 AR. Soluble binding was performed as described under Experimental Procedures. The assay mixture contained purified receptor, with or without 1 M isoproterenol, and 2 nM [ 3 H]DHA, in the absence or presence of the indicated concentrations of zinc. Data obtained were from three independent experiments done in duplicate. All the binding data were analyzed for best fit to two affinity states.
Allosteric Modulation of ␤ 2 AR by Zn
2؉
The function of several Gi-coupled receptors has been shown to be modulated by amiloride analogs and by Na ϩ . This effect has been particularly well characterized for the ␣ 2 -adrenergic receptor (Motulsky and Insel, 1983; Limbird, 1984; Horstman et al., 1990) and for the dopamine D2 (Neve, 1991) and D4 subtypes (Schetz and Sibley, 2001 ). Na ϩ both uncouples the receptor from Gi and reduces agonist affinity. The Na ϩ -sensitive site has been identified in the ␣2-adrenergic receptor (Horstman et al., 1990 ) and the D4 dopamine receptor (Schetz and Sibley, 2001 ) as a conserved Asp residue within the cytoplasmic side of transmembrane 2. This Na ϩ sensitivity may be physiologically relevant, because relatively high local concentrations may be achieved near the cytoplasmic side of the receptor after membrane depolarization.
Recently, the function of the calcium receptor has been shown to be positively modulated by certain L-amino acids (Conigrave et al., 2000a,b) . This may be physiologically relevant because nutrient and Ca 2ϩ homeostasis may be regulated in a coordinate manner.
Zn 2ϩ is an abundant divalent cation in the central nervous system and is released from some synaptic vesicles (Schetz et al., 1999; Weiss et al., 2000) . Zn 2ϩ has been shown to be a noncompetitive blocker of dopamine uptake by the dopamine transporter (Norregaard et al., 1998) and modulates the function of several ligand-gated ion channels. Glycine-induced currents in freshly dissociated rat dorsal motor nucleus neurons are potentiated at low concentrations of Zn 2ϩ (Ͻ3 M) but inhibited at higher concentrations (Ͼ10 M) (Doi et al., 1999) . Zn 2ϩ inhibits ␥-aminobutyratergic currents by slowing the transition rate from closed to open and by accelerating the deactivation kinetics (Barberis et al., 2000) . Of particular interest is the observation that relatively low concentrations of Zn 2ϩ (ϳ10 M) potentiate both agonist binding and peak current in the 5-hydroxytryptamine 3 receptor (Hubbard and Lummis, 2000) .
Less is known about the regulation of G protein-coupled receptor function by Zn 2ϩ . At relatively high concentrations (Ͼ100 M), Zn 2ϩ has been shown to inhibit antagonist binding to the dopamine receptor (D1, D2, and D4 subtypes) Sibley, 1997, 2001) . However, the effect of Zn 2ϩ on agonist binding or G protein activation was not examined. In the case of the D4 dopamine receptor, the Zn 2ϩ binding site that alters antagonist binding is different from the Na ϩ binding site (Schetz and Sibley, 2001) . Zn 2ϩ at high concentrations (Ͼ1 mM) also inhibits binding to the M1 muscarinic receptor (Lu and Hulme, 2000) and the -opioid receptor (Thirstrup et al., 1996) . However, to our knowledge, there has been no report of Zn 2ϩ increasing agonist affinity at these or other GPCRs.
Our findings with the human ␤ 2 AR constitute the first report of Zn 2ϩ as a positive allosteric modulator of agonist binding for a GPCR. The effect of Zn 2ϩ on agonist binding is caused by a direct effect of Zn 2ϩ on the ␤ 2 AR, because it was observed in membranes treated with 7 M urea, a concentration shown previously to strip membranes of both ␣ and ␤␥ G protein subunits (Lim and Neubig, 2001) (Fig. 5B) . Moreover, we observed that Zn 2ϩ enhanced agonist affinity in purified ␤ 2 AR (Fig. 6B) .
While enhancing agonist affinity, Zn 2ϩ seems to uncouple the receptor from Gs, probably due to a direct effect of Zn 2ϩ on Gs, because Zn 2ϩ inhibited basal GTP␥S binding to puri- fied Gs (data not shown). GTP binds to G␣s as a GTP-Mg 2ϩ complex (Birnbaumer and Birnbaumer, 1995) . Zn 2ϩ may form a complex with GTP or interact directly with the Mg 2ϩ binding site on G␣s. However, in intact cells, we observed a small increase in isoproterenol-stimulated cAMP accumulation (Fig. 9B) . This stimulatory effect of Zn 2ϩ on cAMP accumulation is most probably caused by a direct effect of Zn 2ϩ on the ␤ 2 AR, rather than on downstream signaling components, for several reasons. The plasma membrane limits access of Zn 2ϩ to intracellular signaling components. We observe no effect of Zn 2ϩ in the absence of the ␤-agonist. As discussed above, the effect of Zn 2ϩ on Gs is inhibitory and occurs at Zn 2ϩ concentrations greater than 1 M. This inhibitory effect may explain the inhibition of cAMP accumulation that we observe at higher Zn 2ϩ concentrations (Fig. 9) . Moreover, Zn 2ϩ has been reported to be an inhibitor of adenylyl cyclase (Tesmer et al., 1999) . Finally, the cAMP accumulation experiments were done in the presence of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine, and Zn 2ϩ did not augment cAMP-stimulated by forskolin (Fig. 9D) . Therefore, the effect of Zn 2ϩ cannot be explained by inhibition of cAMP hydrolysis. Therefore, we would predict that the Zn 2ϩ enhances cAMP accumulation by an interaction with an extracellular domain of the ␤ 2 AR, possibly the same domain responsible for the positive allosteric effect on agonist binding.
The effect of Zn 2ϩ on antagonist binding seems to be biphasic (Figs. 1A and 5A (Fig. 1C) , and the effects of 1 mM Zn 2ϩ on antagonist binding are not fully reversible in membrane-bound receptor (Fig. 2A) . The fact that binding is almost completely reversible in purified, detergent-soluble receptor suggests that some of the effects of Zn 2ϩ on antagonist binding may be caused by interactions between Zn 2ϩ and phospholipids. Previous studies showed that Zn 2ϩ can alter the properties of phospholipids by interactions with the polar head groups (Binder et al., 2001) . Thus, the effects of Zn 2ϩ on antagonist binding are complex and cannot be explained by noncompetitive inhibition. However, because these effects occur only at relatively high concentrations of Zn 2ϩ (Ͼ100 M), they are not likely to be physiologically important.
Our results are consistent with the existence of at least two Zn 2ϩ binding sites in the ␤ 2 AR, one primarily affecting agonist binding and one primarily affecting antagonist binding. This is further supported by the differential effects of other divalent cations on agonist and antagonist binding. Like Zn 2ϩ , Co 2ϩ enhances agonist binding but has no significant effect on antagonist binding (Fig. 7A) . Ni 2ϩ has only a small effect on antagonist binding, but no significant effect on agonist binding (Fig. 7B) 
